What is Cytiva?
Cytiva operates as a specialized entity within the Research & Development sector, focusing on high-value scientific advancements. With a workforce of 20 to 49 professionals and annual revenues ranging between 1M and 5M, the company serves as a critical node in the UK's biotech ecosystem. Its strategic location in Stevenage, Hertfordshire, places it in proximity to key academic and industrial hubs, facilitating collaborative research and rapid technology transfer. The company's business model is centered on the commercialization of complex R&D outputs, positioning it as a vital partner for organizations seeking to bridge the gap between laboratory discovery and market-ready solutions.
How much funding has Cytiva raised?
Cytiva has raised a total of $4.2M across 2 funding rounds:
Angel/Seed
$1.4M
Series A
$2.8M
Angel/Seed (2014): $1.4M with participation from UCL Business PLC, Imperial Innovations Group plc, and S.R.One Ltd
Series A (2015): $2.8M led by UCL Business, SR One, and Imperial Innovations
Key Investors in Cytiva
UCL Business PLC
UCLB is the commercialisation company of University College London, dedicated to bringing world-leading technologies and innovations to market.
Imperial Innovations Group plc
Imperial College London's enterprise division, focusing on promoting and commercializing innovative technologies developed by world-leading scientists.
S.R. One Ltd
A transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics.
What's next for Cytiva?
With the recent influx of capital, Cytiva is well-positioned to accelerate its strategic objectives. The company is expected to prioritize the scaling of its R&D infrastructure, potentially expanding its headcount to support increased project throughput. Furthermore, the infusion of funds will likely facilitate deeper integration into international markets, leveraging the expertise of its primary backers to navigate the complexities of global life sciences regulation. As the firm transitions into its next phase of growth, the focus will remain on optimizing operational efficiency and securing long-term commercial partnerships that validate its proprietary research methodologies.
See full Cytiva company page
